Biosolution Co.Ltd (086820) fair value: what the stock is really worth
We calculate from audited financials what Biosolution Co.Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Structural break:
The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Weakest SetupStrongly overvalued and low quality.
!Fair value 705.60 KRW · Strongly overvalued (−89%)
!Quality 47/100
!Expensive Growth(revenue 5y +14.4 %/yr)
!Loss over the last twelve months · -15.2% net margin (TTM) · fiscal year 2025 1.8%
!negative free cash flow
✓Ranks above peers(5/8)
!Narrow moat7/100
!Evidence only low, so the estimate is less certain
Watch Biosolution Co.Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range 3,167 KRW – 12,950 KRW · fair‑value band 545.08 KRW – 705.60 KRW · the 6,570 KRW price screens above the 705.60 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide.
Show more
Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2nd-degree burn wounds; and KeraHeal, an autologous spray-type keratinocyte cell-based therapy for skin wounds. It also provides reconstructed human micro-tissue models comprising KeraSkin, an epidermis model; KeraSkin-FT, a full-thickness skin model; KeraSkin-M, a pigmented skin model; corneal models; SoluAirway, a airway mucosa model; SoluOral, an oral mucosa model; SoluDPNeuron, a dopaminergic neuron model; SoluDANeuron, an islet model; and SoluLiver, a liver model. In addition, the company provides human-derived primary cell cultures and primary cells for in vitro research; bio advanced materials; and cosmetics raw materials. The company was formerly known as MCTT Bio Co., Ltd. and changed its name to Bio Solution Co.,Ltd. in January 2016. Bio Solution Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.
Stock analysis
Biosolution Co.Ltd (086820) currently trades at 6,570 KRW, while our model-based Fair Value estimate is 705.60 KRW, implying the stock looks roughly 831.1% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 2,448 KRW per share, and 0 of the 10 models we run sit above the 6,570 KRW price.
Bear case: the Earnings-Based group reads lowest at 175.43 KRW, and 10 of the 10 models stay below the price. Evidence for this calculation is low.
Scenario range: 545.08 KRW (bear) to 705.60 KRW (bull), the price of 6,570 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Biosolution Co.Ltd reported revenue of 15.2B KRW in FY2025 versus 11.8B KRW in FY2021, a compound +6.5%/yr. Reported net income was 273M KRW in FY2025.
Key figures
Market cap 159B KRW (≈ $111M) · P/S ratio 21.0 · Net margin 1.8% · Return on equity −2.5% · Return on assets (EBIT) −6.9% · Operating margin −34.5% · Revenue (TTM) 8.2B KRW · Revenue growth (YoY) +19.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 51% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −89%, 086820 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (175.43 KRW to 2,448 KRW). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear 545.08 KRWFair Value 705.60 KRWBull 705.60 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+17.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.4%
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.5%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−43.0% (2020) → −28.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 645 stocks
Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score46 · Above median
Profitability
Return on assets−3% · Above median
Net margin (TTM)−15% · Below median
Operating margin (TTM)−35% · Bottom 25%
Growth and dividend
Revenue growth20% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/S (TTM)0.01× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Biosolution Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/086820
Frequently asked questions
Is Biosolution Co.Ltd (086820) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 705.60 KRW versus a price of 6,570 KRW, about −89% upside (overvalued).
What is the fair value of 086820?
Our model-based fair value for Biosolution Co.Ltd is 705.60 KRW (as of Sep 13, 2026), built from audited fundamentals. The current price: 6,570 KRW.
What is the quality score of 086820?
Biosolution Co.Ltd has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biosolution Co.Ltd (086820)?
Our model-based price target is the fair value of 705.60 KRW (as of Sep 13, 2026) from 10 valuation models. Cautious scenario 545.08 KRW, optimistic scenario 705.60 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Biosolution Co.Ltd stock forecast for 2026?
Our models put fair value at 705.60 KRW, about −89% upside versus a price of 6,570 KRW (overvalued). Cautious scenario 545.08 KRW, optimistic scenario 705.60 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Biosolution Co.Ltd (086820)?
Biosolution Co.Ltd reported trailing-twelve-month revenue of about 8.2B KRW (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Biosolution Co.Ltd (086820)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biosolution Co.Ltd it is 705.60 KRW per share (as of Sep 13, 2026), against a price of 6,570 KRW. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Biosolution Co.Ltd stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 086820 trades above its calculated fair value: price 6,570 KRW, fair value 705.60 KRW, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 086820?
No. The price is what the market pays today (6,570 KRW); the fair value is what the company's own numbers justify (705.60 KRW). For Biosolution Co.Ltd the two are 5,864 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Biosolution Co.Ltd worth?
The market values Biosolution Co.Ltd at about 159B KRW (market capitalisation, as of Sep 13, 2026). Per share that is 6,570 KRW; our models calculate a fair value of 705.60 KRW per share.
What do the bullish and bearish scenarios say about 086820?
Our models span a range for Biosolution Co.Ltd: cautious scenario 545.08 KRW, base 705.60 KRW, optimistic 705.60 KRW per share (as of Sep 13, 2026, price 6,570 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Biosolution Co.Ltd (086820)?
Balance-sheet figures for Biosolution Co.Ltd (as of Sep 13, 2026): return on equity −2.5%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 086820 from its 52-week high?
Biosolution Co.Ltd trades at 6,570 KRW, about 51% below its 52-week high of 13,450 KRW and 4% above the low of 6,310 KRW (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 705.60 KRW is for.
Which stocks are comparable to Biosolution Co.Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biosolution Co.Ltd stock attractive at the current price?
The data as of Sep 13, 2026: price 6,570 KRW, calculated fair value 705.60 KRW (−89%), Quality Score 47/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 086820 calculated?
We run Biosolution Co.Ltd through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 705.60 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Biosolution Co.Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Biosolution Co.Ltd right now?
The price sits above even our optimistic bull case (705.60 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Biosolution Co.Ltd
How large is the market capitalisation of Biosolution Co.Ltd (086820)?
The market capitalisation of Biosolution Co.Ltd is 159B KRW (≈ $111M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biosolution Co.Ltd (086820)?
The price-to-sales ratio of Biosolution Co.Ltd is 21.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Biosolution Co.Ltd (086820)?
The net margin of Biosolution Co.Ltd is 1.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biosolution Co.Ltd (086820)?
The return on equity (ROE) of Biosolution Co.Ltd is −2.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biosolution Co.Ltd (086820)?
On an EBIT basis the return on assets of Biosolution Co.Ltd is −6.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biosolution Co.Ltd (086820)?
The operating margin of Biosolution Co.Ltd is −34.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biosolution Co.Ltd (086820)?
Revenue at Biosolution Co.Ltd is growing +19.9% versus a year earlier (3y avg +14.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Biosolution Co.Ltd (086820) generate?
The free cash flow of Biosolution Co.Ltd is −2.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Biosolution Co.Ltd (086820) carry?
The net debt of Biosolution Co.Ltd is 17.2B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Biosolution Co.Ltd in the live analysis
One click puts Biosolution Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
